Navigation Links
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/4/2012

THE WOODLANDS, Texas, Jan. 4, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2012 at 9:00 a.m. Pacific Time.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com.  An archived version of the presentation will be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

 


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... & Expo earlier this month, the numbers and momentum ... continue to climb into the billions, more research and ... released 4th Edition State of Legal Marijuana Markets Report ... cannabis-focused data-analysis firm, much of the increase in sector ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
(Date:5/25/2016)... May 25, 2016 Inivata, ... precision of circulating tumour DNA (ctDNA) analysis to ... appointment of Professor Clive Morris as ... across the clinical development programme, scientific collaborations, and ... deliver significant improvements in clinical outcomes for patients. ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated by ... located at 3960 Legacy Drive, Plano, TX and is open 24 hours daily. , ... followed by a medical open house. The Jasper High School band entertained attendees and ...
(Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... day issues, struggles and obstacles veterans’ need to overcome in order to face their ... or retired military veteran(s) with a donated SuperCloset product based on the needs and ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... In a part of the city where’s ... city’s new farm-to-table Kelowna restaurants is hoping to attract diners with a taste ... & Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing ...
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
Breaking Medicine News(10 mins):